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1. Introduction 
Coronary artery disease (CAD) is a major cause of death and disability in developed 
countries. Although CAD mortality rates have declined over the past four decades in the 
United States (and elsewhere), CAD remains responsible for about one-third of all deaths in 
individuals over age 35 [1,2]. It has been estimated that nearly one-half of all middle-aged 
men and one-third of middle-aged women in the United States will develop some 
manifestation of CAD. 
2. Prevalence 
The 2010 Heart Disease and Stroke Statistics update of the American Heart Association 
reported that 17.6 million persons in the United States have CAD, including 8.5 million with 
myocardial infarction (MI) and 10.2 million with angina pectoris [2]. The reported 
prevalence increases with age for both women and men. In a 2009 report that used National 
Health and Nutrition Examination Survey (NHANES) data, MI prevalence was compared 
by sex in middle-aged individuals (35 to 54 years) during the 1998 to 1994 and 1999 to 2004 
time periods [3]. Although MI prevalence was significantly greater in men than women in 
both time periods (2.5 versus 0.7 and 2.2 versus 1.0 respectively), there were trends toward a 
decrease in men and an increase in women. Data from NHANES (and other databases) that 
rely on self-reported MI and angina from health interviews probably underestimate the 
actual prevalence of advanced CAD.  
This is likely as advanced occlusive coronary artery disease often exists with few symptoms 
or overt clinical manifestations. Silent ischemia, which is thought to account for 75 percent 
of all ischemic episodes [4], may be brought to light by electrocardiographic changes (ST 
segment depression) on an exercise test, ambulatory 24 hour electrocardiographic recording, 
or periodic routine electrocardiogram (ECG). 
3. Global trends 
Heart disease mortality has been declining in the United States and in regions where 
economies and health care systems are relatively advanced, but the experience is often quite 
different around the world [5]. Coronary artery disease is the number one cause of death in 
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adults from both low- and middle income countries as well as from high-income countries 
[5]. At the turn of the century, it was reported that CAD mortality was expected to increase 
approximately 29 percent in women and 48 percent in men in developed countries between 
1990 and 2020. The corresponding estimated increases in developing countries were 120 
percent in women and 137 percent in men [6]. 
The most dramatic increments in ischemic heart disease events on a percentage basis were 
forecast for the Middle East and Latin America. The experience in Asia is especially 
important because of the large populations involved. In India, CAD may not be largely 
explained by traditional risk factors [7]. In China, risk factor trends complement tracking of 
event rates. For example, the dramatic increase in CAD mortality in Beijing is attributable to 
greater cholesterol levels. The mean cholesterol level was 4.30 mmol/L (166 mg/dL) in 1984 
and 5.33 mmol/L (206 mg/dL) only 15 years later [8]. In Latin America, declines in vascular 
disease rates have been less favorable than in the United States; unfavorable trends in 
physical activity, obesity, and smoking contribute to these differences [9].  
International leaders have called for action plans to avert the projected global epidemic of 
ischemic heart disease in developing countries [10]. 
4. Pathophysiology 
4.1 Cellular level 
Angina is caused by myocardial ischemia, which occurs whenever myocardial oxygen 
demand exceeds oxygen supply (Figure 1). Because oxygen delivery to the heart is closely  
Cellular Mechanism of Ischemia
Consequence(s) of Mechanical Dysfunction
Mechanical Dysfunction
 Abnormal Contraction and Relaxation
  Diastolic Tension
O2 Consumption
(to maintain tonic contraction)

ATP Hydrolysis




 Blood Flow to Microcirculation
(O2 delivery to Myocytes)
Belardinelli et al. Eur Heart 8 (Suppl. A):A10-A13, 2006  
Fig. 1.  
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coupled to coronary blood flow, a sudden cessation of regional perfusion following a 
thrombotic coronary occlusion quickly leads to the cessation of aerobic metabolism, 
depletion of creatine phosphate, and the onset of anaerobic glycolysis. This is followed by 
the accumulation of tissue lactate, a progressive reduction in tissue ATP levels, and an 
accumulation of catabolites, including those of the adenine nucleotide pool. As ischemia 
continues, tissue acidosis develops and there is an efflux of potassium into the extracellular 
space. Subsequently, ATP levels fall below those required to maintain critical membrane 
function, resulting in the onset of myocyte death. Irreversible myocardial injury begins after 
20 minutes of coronary occlusion in the absence of significant collaterals [11]. 
Irreversible injury begins in the subendocardium and progresses as a wave front over time, 
from the subendocardial layers to the subepicardial layers. This reflects the higher oxygen 
consumption in the subendocardium and the redistribution of collateral flow to the outer 
layers of the heart by the compressive determinants of flow at reduced coronary pressure. 
Factors that increase myocardial oxygen consumption (e.g., tachycardia) or reduce oxygen 
delivery (e.g., anemia, arterial hypotension) accelerate the progression of irreversible injury. 
In contrast, repetitive reversible ischemia or angina prior to an occlusion can reduce 
irreversible injury through preconditioning [12].  
4.2 Anatomical level 
Acute coronary syndrome is usually caused by an unstable atherosclerotic plaque rupture 
with subsequent platelet-rich thrombus overlying the culprit lesion causing severe 
narrowing (Figure. 2). This abrupt decrease in blood supply often results in chest pain and 
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enzyme elevation. Less commonly, non ST elevation myocardial infarction is caused by 
diseases in which myocardial demand exceeds myocardial supply causing a similar clinical 
presentation. These diseases usually cause a hypermetabolic or high cardiac output state 
and include hyperthyroidism, anemia, fever, pheochromocytoma, hypertrophic 
cardiomyopathy, AV fistula and hypertensive urgency/emergency. 
Whatever the mechanism of angina may be, patients usually develop the clinical 
manifestations in a sequence as described in Figure 3. Note that diastolic dysfunction is the 
earliest manifestation of ischemia, next to perfusion abnormalities which are seen in nuclear 
studies.  
5. Clinical features 
Coronary artery disease could be manifesting as a continuum from stable angina to acute 
coronary syndrome. Angina pectoris is a discomfort in the chest or adjacent areas caused by 
myocardial ischemia. It is usually brought on by exertion and is associated with a 















Increasing Degree and Duration of Ischemia








Heberden's initial description of angina as conveying a sense of “strangling and anxiety” is 
still remarkably pertinent. Other adjectives frequently used to describe this distress include 
viselike, constricting, suffocating, crushing, heavy, and squeezing. In other patients, the 
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quality of the sensation is more vague and described as a mild pressure-like discomfort, an 
uncomfortable numb sensation, or a burning sensation.  
The site of the discomfort is usually retrosternal, but radiation is common and usually 
occurs down the ulnar surface of the left arm; the right arm and the outer surfaces of both 
arms may also be involved. Epigastric discomfort alone or in association with chest pressure 
is not uncommon. Anginal discomfort above the mandible or below the epigastrium is rare. 
Anginal equivalents (i.e., symptoms of myocardial ischemia other than angina), such as 
dyspnea, faintness, fatigue, and eructations, are common, particularly in the elderly. 
A history of abnormal exertional dyspnea may be an early indicator of CAD even when 
angina is absent or no evidence of ischemic heart disease can be found on the 
electrocardiogram (ECG). Dyspnea at rest or with exertion may be a manifestation of severe 
ischemia, leading to increases in left ventricular (LV) filling pressure. Nocturnal angina 
should raise the suspicion of sleep apnea.  
The term acute coronary syndrome (ACS) is applied to patients in whom there is a suspicion 
of myocardial ischemia. There are three types of ACS: ST elevation (formerly Q-wave) MI 
(STEMI), non-ST elevation (formerly non-Q wave) MI (NSTEMI), and unstable angina (UA). 
The first two are characterized by a typical rise and/or fall in biomarkers of myocyte injury.  
For many years, the diagnosis of acute MI relied on the revised criteria established by the 
World Health Organization (WHO) in 1979. These criteria were epidemiological and aimed 
at specificity. A joint European Society of Cardiology (ESC) and American College of 
Cardiology (ACC) committee proposed a more clinically based definition of an acute, 
evolving, or recent MI in 2000 (13). In 2007 the Joint Task Force of the European Society of 
Cardiology, American College of Cardiology Foundation, the American Heart Association, 
and the World Health Federation (ESC/ACCF/AHA/WHF) refined the 2000 criteria and 
defined acute MI as a clinical event consequent to the death of cardiac myocytes (myocardial 
necrosis) that is caused by ischemia (as opposed to other etiologies such as myocarditis or 
trauma) [14]. 
The criteria used to define MI differ somewhat depending upon the particular clinical 
circumstance of the patient: those suspected of acute MI based upon their presentation, 
those undergoing either coronary artery bypass graft surgery or percutaneous intervention, 
or those who have sustained sudden unexpected, cardiac arrest with or without death [14].  
For patients who have undergone recent revascularization or who have sustained cardiac 
arrest or death, the criteria for the diagnosis of MI are given in detail in the Table 1. 
For all other patients in whom there is a suspicion of MI, a typical rise and/or gradual fall 
(troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial 
necrosis, with at least one of the following is required: 
 Ischemic symptoms 
 Development of pathologic Q waves on the ECG 
 ECG changes indicative of ischemia (ST segment elevation or depression) 
 Imaging evidence of new loss of viable myocardium or a new regional wall motion 
abnormality. 
In addition, pathologic findings (generally at autopsy) of an acute MI are accepted criteria. 
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The joint task force [14] further refined the definition of MI by developing a clinical 
classification according to the assumed proximate cause of the myocardial ischemia.  
Patulous aneurysmal dilation involving most of the length of a major epicardial coronary 
artery is present in approximately 1 to 3 percent of patients with obstructive CAD at 
autopsy or angiography. This angiographic lesion does not appear to affect symptoms, 
survival, or incidence of MI. Most coronary artery ectasia and/or aneurysms are caused by 
coronary atherosclerosis (50 percent), and the rest are caused by congenital anomalies and 
inflammatory diseases, such as Kawasaki disease.  
 
Table 1. Types of Myocardial Infarction 
6. Diagnosis 
Evaluation of new onset chest pain in stable individuals should begin with the consideration 
of imminently life-threatening causes (including acute coronary syndrome, pulmonary 
embolus, aortic dissection, pneumothorax, and esophageal rupture). This is usually 
accomplished using clinical judgement, along with ECG testing, and less frequently exercise 
testing, other noninvasive testing, or invasive angiography.  
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This is being discussed in detail by other authors in various chapters. nce a life-threatening 
etiology has been excluded, attempts should be made to identify the specific cause of 
symptoms and begin treatment. A diagnostic pattern will frequently emerge, based upon 
the patient's risk factors, description of the pain, and associated symptoms. 
Standard clinical characteristics routinely obtained during the initial medical evaluation of 
patients with UA/NSTEMI can be used to construct a simple classification system that is 
predictive of risk for death and cardiac ischemic events. The TIMI (Thrombolysis in 
Myocardial Infarction) risk score (Table 2) includes variables that can be easily ascertained 
when a patient with UA/NSTEMI presents to the medical care system. The variables used to 
construct the score were based on observations from prior studies of risk stratification and 
incorporate demographic and historical features of the patient, measures of the tempo and 
acuity of the presenting illness, and indicators of the extent of myocardial ischemia and 
necrosis.  
Since patients with an acute coronary syndrome are at increased risk of death and nonfatal 
cardiac events, clinicians must assess prognosis on an individual basis to formulate plans for 
evaluation and treatment. The TIMI risk score for UA/NSTEMI is a simple prognostication  
  
Table 2. TIMI Risk Score for Unstable Angina/Non-ST Elevation MI 
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scheme that enables a clinician to categorize a patient's risk of risk of death and ischemic 
events at the critical initial evaluation. A promising clinical application of this score is 
identification of a patient for whom new antithrombotic therapies would be especially 
effective.  
While ECG manifestations are an important component of diagnosis, one should be aware 
of the pitfalls of the ECG. Tables 3, 4 and 5 describe the ECG manifestations of ischemic 








Table 4. ECG changes associated with prior myocardial infarction 
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Table 5. Common ECG pitfalls in diagnosing myocardial infarction 
7. Management 
Patients with an initial ECG reading that reveals new or presumably new ST segment depression 
and/or T wave inversion, although not considered candidates for fibrinolytic therapy, should be 
treated as though they are suffering from MI without ST elevation or unstable angina (a 
distinction to be made subsequently after scrutiny of serial ECGs and serum cardiac marker 
measurements). In patients with a clinical history suggestive of STEMI and an initial 
nondiagnostic ECG reading (i.e., no ST segment deviation or T wave inversion), serial tracings 
should be obtained while the patients are being evaluated in the emergency department.  
Emergency department staff can be alerted to the sudden development of ST segment 
elevation by periodic visual inspection of the bedside ECG monitor, by continuous ST segment 
recording, or by auditory alarms when the ST segment deviation exceeds programmed limits. 
Decision aids such as computer-based diagnostic algorithms, identification of high-risk clinical 
indicators, rapid determination of cardiac serum markers, two-dimensional echocardiographic 
screening for regional wall motion abnormalities, and myocardial perfusion imaging have 
greatest clinical utility when the ECG reading is nondiagnostic. In an effort to improve the 
cost-effectiveness of care of patients with a chest pain syndrome, nondiagnostic ECG reading, 
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and low suspicion of MI but in whom the diagnosis has not been entirely excluded, many 
medical centers have developed critical pathways that involve a coronary observation unit 
with a goal of ruling out MI in less than 12 hours. 
Once the diagnosis of coronary artery disease is made, the management depends upon the 
severity of the underlying severity of the disease. The treating physician has to diagnose the 
clinical scenario appropriately as the treatment largely depends of the initial diagnosis. 
Stable coronary artery disease could be managed conservatively whereas acute coronary 
syndrome has to be managed very aggressively. Select patients have to be considered for 
early invasive strategy too.   
The prehospital care of patients with suspected STEMI is a crucial element bearing directly 
on the likelihood of survival. Most deaths associated with STEMI occur within the first hour 
of its onset and are usually caused by ventricular fibrillation. Accordingly, the importance of 
the immediate implementation of definitive resuscitative efforts and of rapidly transporting 
the patient to a hospital cannot be overemphasized.  
Major components of the delay from the onset of symptoms consistent with acute myocardial 
infarction (MI) to reperfusion include the following: (1) the time for the patient to recognize the 
seriousness of the problem and seek medical attention; (2) prehospital evaluation, treatment, 
and transportation; (3) the time for diagnostic measures and initiation of treatment in the 
hospital (e.g., “door-to-needle” time for patients receiving a thrombolytic agent and “door-to-
balloon” time for patients undergoing a catheter-based reperfusion strategy); and (4) the time 
from initiation of treatment to restoration of flow (Figure 4). Thrombolytic therapy is vital for 
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Adjunctive medical therapy is a critical component of therapy for STEMI and confers benefit in 
addition to that gained by reperfusion therapies, regardless of method of reperfusion (Table 6).  
Ancillary therapy can be used to facilitate and enhance coronary reperfusion or to limit the 
consequences of myocardial ischemia. Early, aggressive use of antiplatelet therapies, such as 
aspirin, and clopidogrel, confers significant additional mortality benefit when given as 
adjuncts to thrombolysis or PCI. Beta-blockers, angiotensin-converting enzyme inhibitors in 
appropriately selected patients, and 3-hydroxy-3-methylglutaryl CoA reductase inhibitors 
(statins) have all been shown to reduce the risk of cardiovascular events and mortality in 
patients who have STEMI. Therapies such as nitroglycerin and morphine have no mortality 
benefit but may improve symptoms and reduce ischemic burden. Calcium-channel blockers 
and prophylactic anti-arrhythmic drug therapy (lidocaine) may increase mortality. The 
suggested benefit of metabolic modulation at the myocyte level with electrolytes, glucose, 
and insulin seen in small, early trials has not been reproduced in larger, randomized studies.  
 








Although improvements in the management of patients who have STEMI have led to a 
decline in acute and long-term fatality rates, reperfusion and ancillary therapies remain 
underused. Several initiatives (eg. Get With the Guidelines in USA) are designed to improve 
adherence to guidelines and access to appropriate reperfusion therapies. To date, clinical 
advancement is judged on achieving and maintaining epicardial artery patency. New 
fibrinolytics and combination therapies will continue to evolve. There will be technological 
advances and improvement in operator skills for PCI. The ultimate goal for the management 
of STEMI remains unchanged: to open occluded arteries quickly in carefully screened 
patients and in a cost-effective manner. 
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